Detail akcie AbbVie Inc online

Business Summary: AbbVie Inc. is a diversified research-based biopharmaceutical company engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. It offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383 for the treatment of inflammatory bowel disease.
Financial Summary: BRIEF: For the six months ended 30 June 2024, AbbVie Inc revenues increased 3% to $26.77B. Net income applicable to common stockholders increased 21% to $2.72B. Revenues reflect pharmaceutical products segment increase of 93% to $26.77B. Net income benefited from pharmaceutical products segment income increase of 51% to $6.8B. Dividend per share increased from $2.96 to $3.10.